Michael Linn
Overview
Explore the profile of Michael Linn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
441
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frane N, Iturriaga C, Bub C, Regala P, Katsigiorgis G, Linn M
J Clin Orthop Trauma
. 2020 Nov;
11(6):1110-1116.
PMID: 33192016
Background: Open pelvic fractures are rare injuries, associated with high patient morbidity and mortality. Few studies have investigated the impact of patient demographics, comorbidities, and injury related factors on complication...
2.
Linn M, Schwartz A
JBJS Case Connect
. 2017 Dec;
4(1 Suppl 2):e8.
PMID: 29252554
No abstract available.
3.
Shillito M, Linn M, Girard P, Schwartz A
JBJS Case Connect
. 2017 Dec;
4(3):e78.
PMID: 29252298
No abstract available.
4.
Higgins B, Glenn K, Walz A, Tovar C, Filipovic Z, Hussain S, et al.
Clin Cancer Res
. 2014 May;
20(14):3742-52.
PMID: 24812409
Purpose: Antitumor clinical activity has been demonstrated for the MDM2 antagonist RG7112, but patient tolerability for the necessary daily dosing was poor. Here, utilizing RG7388, a second-generation nutlin with superior...
5.
Ball S, Severns D, Linn M, Meyer R, Swenson F
J Arthroplasty
. 2013 Aug;
28(8 Suppl):53-5.
PMID: 23948123
Serum cobalt (Co) and chromium (Cr) levels are commonly used to screen for excessive wear of metal-on-metal hip replacements. However, it is unknown how rapidly these should decline after revision....
6.
Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, et al.
Cancer Res
. 2013 Feb;
73(8):2587-97.
PMID: 23400593
MDM2 negatively regulates p53 stability and many human tumors overproduce MDM2 as a mechanism to restrict p53 function. Thus, inhibitors of p53-MDM2 binding that can reactivate p53 in cancer cells...
7.
Linn M, Collnot E, Djuric D, Hempel K, Fabian E, Kolter K, et al.
Eur J Pharm Sci
. 2011 Dec;
45(3):336-43.
PMID: 22172603
As many new active pharmaceutical ingredients are poorly water soluble, solubility enhancers are one possibility to overcome the hurdles of drug dissolution and absorption in oral drug delivery. In the...
8.
Kolinsky K, Tovar C, Zhang Y, Railkar A, Yang H, Carvajal D, et al.
Cancer Chemother Pharmacol
. 2011 May;
68(6):1585-94.
PMID: 21553286
Purpose: This study describes the antiproliferative activity of the multikinase inhibitor R1530 in vitro and its antitumor and anti-angiogenic activity, pharmacokinetics, and tolerability in vivo. Methods: The antiproliferative activity of...
9.
Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, et al.
Cancer Res
. 2009 Sep;
69(19):7672-80.
PMID: 19773430
Notch signaling is an area of great interest in oncology. RO4929097 is a potent and selective inhibitor of gamma-secretase, producing inhibitory activity of Notch signaling in tumor cells. The RO4929097...
10.
Higgins B, Kolinsky K, Linn M, Adames V, Zhang Y, Moisa C, et al.
Anticancer Res
. 2007 Aug;
27(4B):2279-87.
PMID: 17695515
Background: Capecitabine and bevacizumab have each been shown to inhibit tumor growth. Their combination failed to improve survival in a phase III trial of metastatic breast cancer (MBC), although it...